Podophyllotoxin (PPT) has anticancer activity but its clinical use is limited by poor aqueous solubility and significant systemic toxicity. The study aimed to overcome these limitations by developing a targeted nanomedicine that improves PPT delivery to tumors while reducing off-target toxicity. The authors focused on exploiting CD44 receptor targeting through hyaluronic acid (HA) and on designing a cleavable linker that responds to tumor microenvironment (TME) cues.
The investigators engineered prodrug micelles (termed HPMs) by conjugating PPT to an HA polymer backbone. Conjugation used a flexible linker, adipic dihydrazide-3,3'-dithiodipropionic acid (ADH-DTDPA), to create a dual-cleavable spacer between HA and PPT. The conjugates self-assembled into micelles intended to provide passive accumulation at tumor sites and active targeting via HA–CD44 interactions.
The ADH-DTDPA spacer was selected to provide dual-stimuli responsiveness: sensitivity to acidic pH and to reducing conditions characteristic of the TME. In vitro experiments showed rapid micelle disassembly under tumor-like conditions (pH 5.0 with elevated glutathione (GSH)), consistent with a design that releases PPT preferentially within the intracellular or intratumoral milieu.
Cellular uptake studies were performed using the human lung cancer cell line NCI-H1299. HPMs demonstrated efficient internalization that the authors attribute to CD44-mediated endocytosis, consistent with HA-based targeting. The in vitro behavior indicates that HA on the micelle surface facilitates recognition and uptake by CD44-expressing tumor cells.
To quantify the molecular interaction underlying the targeting mechanism, the authors used microscale thermophoresis (MST). MST measurements provided a dissociation constant of KD = 15.3 μM for binding between the HA-based construct and the CD44 receptor. This quantitative binding data supports the hypothesis that HA–CD44 affinity contributes to the observed cellular uptake and targeting.
In vivo experiments showed that the HPM formulation achieved effective accumulation at tumor sites. Antitumor efficacy was assessed by comparing HPMs with free PPT: HPMs administered at 10 mg/kg produced superior tumor inhibition relative to free PPT given at 15 mg/kg. These findings indicate that the prodrug micelle design enhanced therapeutic efficacy while using a lower PPT dose than the free drug in the reported model.
Safety assessment in the reported in vivo studies indicated that treatment with HPMs did not induce hepatotoxicity or nephrotoxicity, in contrast to concerns typically associated with systemic PPT administration. The authors highlight the absence of observable liver and kidney toxicity as evidence of an improved safety profile for the HPM formulation in their experimental conditions.
The study presents a rationally designed HA–PPT prodrug micelle that combines CD44-targeted delivery with a dual-cleavable, TME-responsive linker. Quantitative MST measurements (KD = 15.3 μM) provide molecular-level support for the targeting mechanism. In vivo, HPMs accumulated at tumors, achieved superior tumor inhibition at a lower PPT dose (10 mg/kg vs 15 mg/kg for free PPT), and did so without inducing hepatotoxicity or nephrotoxicity in the experiments reported. The authors propose that this approach may address PPT’s solubility and systemic toxicity issues and offers quantitative insight applicable to the design of targeted nanomedicines for lung cancer therapy.
The abstract and provided record summarize in vitro and in vivo preclinical findings but do not provide full experimental details, raw data, or extended safety profiling in humans. Specifics of formulation parameters, full toxicology panels, long-term safety, and clinical translation steps were not reported in the source abstract and would require consultation of the full text for comprehensive assessment.